GLP-1 RAs Show Mixed Pancreatitis Risk - Summary - MDSpire
From the Journals

GLP-1 RAs Show Mixed Pancreatitis Risk

Early increase in suspected drug-induced cases offset by later lower rates of alcohol- and triglyceride-associated pancreatitis

  • By

  • Andrea Surnit

  • May 5, 2026

  • 4 min

Share

A study evaluating the safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) found that initiating GLP-1 RAs did not lead to a higher rate of acute pancreatitis after one year compared to sulfonylureas among patients with type 2 diabetes. Analyzing data from 333,687 patients between 2017 and 2023, researchers noted a slight increase in suspected drug-induced pancreatitis shortly after initiation of GLP-1 RAs, but this was offset by lower rates of alcohol-induced and hypertriglyceridemia-associated pancreatitis later. The findings highlight the need for early monitoring when starting GLP-1 RAs. Most participants were older men, limiting the findings' generalizability.

Original Source(s)

GLP-1 RAs Show Mixed Pancreatitis Risk

  • by Andrea Surnit

  • May 5, 2026

Related Content

CGM Shows Potential for Diagnosing Diabetes in Pregnancy

Early glucose patterns may help identify risk, but evidence doesn't support replacing standard testing.

Weight-loss Drug Response Varies, But Why?

Study links DNA variants to weight loss and side effects

  • May 5, 2026

  • 2 min
This Week’s CGT News: CRISPR Hits Phase 3 Milestone

Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal

  • May 4, 2026

  • 7 min